
|Videos|July 2, 2013
Episode 4- Characterizing Multiple Sclerosis
Advertisement
Episodes in this series

During this discussion about the characterization of multiple sclerosis (MS), Fred Lublin, MD, defines the 4 subtypes of MS: relapsing-remitting MS, secondary-progressive MS, primary-progressive MS, and progressive-relapsing MS.
Patricia K. Coyle, MD, joins the discussion and describes the relationship between clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) to MS. Dr Coyle explains the importance of these more recent clinical courses when studying the diagnosis or development of MS.
Advertisement
Related to this article

In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy in aNSCLC.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."
Advertisement
Advertisement
Trending on AJMC
1
Value-Based Pilot for Medicaid Members With Substance Use Disorder
2
Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies
3
Real-World Brexu-cel Results in MCL Mirror Trials; Cost, QOL Data Lag
4
Four Ways to Boost Awareness, Access for COVID-19 PEP
5

















